Developmental Therapeutics Program

One Dose Mean Graph

NSC: 774732 / 1	**Conc:** 1.00E-5 Molar	**Test Date:** Apr 22, 2013
Experiment ID: 1304OS71		**Report Date:** Jun 13, 2013

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	105.85
HL-60(TB)	-79.18
K-562	-78.06
MOLT-4	-75.26
RPMI-8226	104.93
Non-Small Cell Lung Cancer	
A549/ATCC	101.73
HOP-62	111.47
HOP-92	101.32
NCI-H226	92.80
NCI-H23	110.40
NCI-H322M	101.22
NCI-H460	100.60
NCI-H522	100.37
Colon Cancer	
COLO 205	119.59
HCC-2998	101.64
HCT-116	104.50
HCT-15	101.50
HT29	114.58
KM12	112.44
SW-620	103.13
CNS Cancer	
SF-268	103.33
SF-295	102.81
SF-539	105.80
SNB-19	105.08
SNB-75	76.53
U251	101.21
Melanoma	
LOX IMVI	96.26
MALME-3M	121.66
M14	101.32
MDA-MB-435	112.95
SK-MEL-2	119.56
SK-MEL-28	112.21
SK-MEL-5	99.56
UACC-257	95.59
UACC-62	105.67
Ovarian Cancer	
IGROV1	108.74
OVCAR-3	113.89
OVCAR-4	99.52
OVCAR-5	107.13
OVCAR-8	98.42
NCI/ADR-RES	105.45
SK-OV-3	106.55
Renal Cancer	
786-0	102.43
A498	78.81
ACHN	106.89
CAKI-1	101.77
RXF 393	98.97
SN12C	100.68
TK-10	101.95
UO-31	91.26
Prostate Cancer	
PC-3	97.28
DU-145	111.68
Breast Cancer	
MCF7	91.31
MDA-MB-231/ATCC	114.90
HS 578T	98.13
BT-549	115.09
T-47D	98.38
MDA-MB-468	93.14
Mean	94.09
Delta	173.27
Range	200.84

Mean Growth Percent - Growth Percent